CN
菜单
R&D
R&D Pipeline

Building balanced and differentiated pipeline covering products from early- to late-stage through both in-house development and in-licensing.


.

Assets
Indication
Combo
Development area
Pre-clinical
Phase I
Phase II
Phase III
NDA
Commercial Rights
Utidelone Injection
Advanced breast cancer
Xeloda
CN
Global
Xeloda
Global
Global
Advanced non-small cell lung cancer
Monotherapy
CN
Global
Monotherapy
Global
Global
Breast cancer neoadjuvant
AC
CN
Global
Solid tumors
Monotherapy／PD-1
CN
Global
Breast cancer brain metastasis
VEGF mAb
US
Global
Lung cancer brain metastasis
VEGF mAb
CN
Global
Glioblastoma
VEGF mAb
CN & US
Global
Utidelone Capsule
Solid tumors
Monotherapy
US
Global
Monotherapy／Xeloda
CN
Global
Advanced breast cancer
Xeloda
CN
Global
Advanced gastric and esophageal cancers
PD-1
CN & US
Global
Advanced liver cancer
PD-1
CN
Global
Advanced ovarian cancer
VEGF mAb
CN & US
Global
Utidelone nano-injection
Solid tumors
TBD
CN
Global
Utidelone antibody-drug conjugate
Solid tumors
TBD
Global
Global
BG22
Solid tumors
TBD
Global
Global
BG18
Solid tumors
TBD
Global
Global
BG44
Solid tumors
TBD
Global
Global
Note:

Abbreviations: Xeloda: capecitabine; AC: anthracycline and cyclophosphamide; VEGF mAb: vascular endothelial growth factor monoclonal Antibody; TBD: to be determined.